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PURPOSE. To investigate the action of sphingosine-1-phosphate (S1P) in adipocyte differenti-
ation of orbital fibroblasts and determine its putative role in the pathogenesis of Graves’
orbitopathy (GO).
METHODS. Primary preadipocyte orbital fibroblast cultures were stimulated for adipogenesis.
Real-time PCR was performed to evaluate the expression of S1P receptor mRNA. To evaluate
the effect of S1P and S1P receptor blockers (W146 and FTY720) on adipocyte differentiation,
cultures were exposed to each receptor blocker for the first 4 days of the differentiation
period. Differentiated cells were stained with Oil Red O, and the production of peroxisome
proliferator activator gamma (PPARc) and CCAAT-enhancer-binding proteins (C/EBP) a and b
were determined by Western blot analysis.
RESULTS. Sphingosine-1-phosphate receptor 1, 2, and 3 mRNA expression levels were
significantly higher in GO tissue samples than non-GO. Sphingosine-1-phosphate receptor 1
through 5 mRNA expression was significantly increased during the 10 days of adipogenesis.
Sphingosine-1-phosphate treatment increased the size and number of adipocytes, and
increased the expression of adipogenic transcriptional regulators. Treatment with S1P1
receptor inhibitor (W146) for 4 days after induction of adipogenesis attenuated adipocyte
differentiation. Sphingosine-1-phosphate receptor blocker also decreased reactive oxygen
species (ROS) production in GO orbital fibroblasts and H2O2-stimulated HO-1 production in
GO orbital fibroblasts. S1P1 receptor inhibitor reduced the number of adipocytes and
suppressed the accumulation of lipid droplets induced by 10 lM H2O2 or 2% cigarette smoke
extract (CSE) treatment.
CONCLUSIONS. Sphingosine-1-phosphate could play a role in orbital adipocyte differentiation of
GO. Modulation of S1P actions may provide a therapeutic target for the treatment of GO.
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Graves’ orbitopathy (GO) is an autoimmune disease thatoccurs in up to 50% of patients with Graves’ disease.1
Severe and potentially blinding orbital inflammation develops
in approximately 5% to 6% of these patients.2 The inflammation
causes muscle and soft tissue swelling, which, when progres-
sive, can result in clinical features of proptosis, exposure
keratopathy, and compressive optic neuropathy.
Current evidence points to orbital fibroblasts as the target
cells in GO and suggests that their normal functions are
dysregulated through autoimmune mechanisms.3 These orbital
fibroblasts secrete large quantities of hyaluronan in response to
various cytokines, and a subgroup of the orbital fibroblasts then
differentiate into mature adipocytes that have increased
thyrotropin receptor production.4,5 These cellular changes
lead to enlargement of extraocular muscles and expansion of
orbital fat in GO patients.
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid
that mediates diverse cellular responses such as proliferation,
cytoskeletal organization and migration, immune cell traffick-
ing, adherence and tight junction assembly, and differentia-
tion.6,7 Sphingosine-1-phosphate is formed by the action of
sphingosine kinase (SphK), which converts sphingosine and
ATP to S1P. Most of its best-characterized actions are mediated
through a family of five G protein-coupled receptors, the S1P 1
through 5 receptors, which couple to a variety of G proteins
allowing them to mediate many different biologic responses.6,8
Among the several interesting actions of S1P, a great deal of
attention has been focused on its effects on the process of
differentiation. The S1P/S1P1 receptor system plays a crucial
role in promoting angiogenesis by regulating differentiation of
vascular endothelial cells.9,10 Sphingosine-1-phosphate also
promotes myogenic differentiation of the mouse C2C12 skeletal
myocyte cell line,11 and modulates mouse osteoclast differen-
tiation.12 Recently, Hashimoto et al.13 reported that sphingosine
kinase and S1P are upregulated during adipogenesis and play a
significant role in adipocyte differentiation in mouse 3T3-L1
cells. Also, in 3T3-L1 preadipocytes the expression of 11b-
hydroxysteroid dehydrogenase type 1 (11b-HSD1), which is
known to contribute to adipose tissue differentiation and
dysfunction, is robustly induced when cells are treated with
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S1P.14,15 Conversely, FTY720, a synthetic analogue of S1P,
which acts as a functional antagonist of S1P, downregulates
adipogenic differentiation.16
To date, no studies have evaluated the expression of S1P
receptors and the action of S1P in orbital fibroblasts and its
putative role in adipocyte differentiation, one of the most
important features of pathogenesis of GO. Here, we hypoth-
esized that S1P could play a role in orbital adipocyte
differentiation, and modulation of this bioactive mediator
may provide a therapeutic target for the treatment of GO.
MATERIALS AND METHODS
Reagents and Chemicals
Sphingosine-1-phosphate (S1P) and FTY720 were purchased
from Sigma-Aldrich Corp. (St. Louis, MO, USA). Sphingosine-1-
phosphate receptor 1 antagonist, W146 (trifluoroacetate salt)
was purchased from Cayman Chemical (Ann Arbor, MI, USA).
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum (FBS), penicillin, and gentamycin were purchased from
Hyclone Laboratories, Inc. (Logan, UT, USA). The 3-(4,5-
dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay and Oil Red O were purchased from Sigma Aldrich, Inc.
Anti-peroxisome proliferator activator gamma (PPARc), anti-
CCAAT-enhancer-binding protein (C/EBP) a, anti-C/EBP b, anti-
heme oxygenase (HO)-1, anti-extracellular-regulated kinase
(ERK) 1/2, anti-phospho ERK 1/2, anti–phospho-Akt, and
anti–b-actin antibodies were all obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Orbital adipose/connective tissue specimens were obtained
during the orbital decompression surgery for severe GO (n¼5;
three women and two men, aged 29–59 years) (Table). The GO
patients had not received steroid medication for at least 3
months before surgery, and were euthyroid at the time of
surgery. The clinical activity scores (CAS) at the time of tissue
harvest were less than four for all patients, indicating inactive
inflammatory status, which was based on an original 10-point
CAS scale developed by Mourits et al.17 No patients had been
previously treated with orbital radiotherapy. Normal orbital
adipose/connective tissue specimens were collected during
the course of orbital surgery for other noninflammatory
problems from patients with no prior history of thyroid
disease or GO and with no clinical evidence of GO (n¼ 5; five
women, aged 36–64 years). The institutional review board of
Severance Hospital, Yonsei University College of Medicine
(Seoul, Korea), approved the study and written informed
consent was obtained from all participants. This study followed
the tenets of the Declaration of Helsinki, and written informed
consent was obtained from the subjects after explanation of
the nature and possible consequences of the study.
Cell Culture and Differentiation Protocol
Tissue explants were minced and placed directly in plastic
culture dishes in DMEM:F12 (1:1) containing 20% FBS,
penicillin (100 U/mL), and gentamycin (20 lg/mL), allowing
preadipocyte fibroblasts to proliferate. After fibroblasts had
grown out from the explants, monolayers were passaged
serially by gently treating with trypsin/EDTA, and cultures
were maintained in 80-mm flasks containing DMEM with 10%
FBS and antibiotics. Cell cultures were grown in a humidified
5% CO2 incubator at 378C. The strains were stored in liquid N2
until needed, and were used between the second and fifth
passage.
After cells reached confluence in 6-well plates, differenti-
ation of adipocytes was initiated by the following protocol. The
culture medium was changed to serum-free DMEM supple-
mented with 33 lM biotin, 17 lM pantothenic acid, 10 lg/mL
transferrin, 0.2 nM T3, 1 lM insulin (Boehringer-Mannheim,
Mannheim, Germany), and 0.2 lM carbaprostaglandin (cPGI2;
Calbiochem, La Jolla, CA, USA). For the first 4 days, 1 lM
insulin, 1 lM dexamethasone, and 0.1 mM isobutylmethylxan-
thine were included in the media. The differentiation was
continued for 10 days, during which the media was replaced
every 2 to 3 days. A PPARc agonist, rosiglitazone (10 lM,
Cayman, Ann Arbor, MI, USA), was added from day 1 for further
stimulation of adipogenesis.18 To evaluate the effect of S1P and
S1P receptor blockers (W146 and FTY720) on adipocyte
differentiation, we exposed cultures to S1P and S1P receptor
blockers for the first 4 days of the differentiation period.
Real-Time PCR
Total RNA (1 lg) was isolated and reverse transcribed into
complementary DNA according to the manufacturer’s instruc-
tions (#74104; Qiagen, Valencia, CA, USA). The resulting cDNA
was amplified using an ABI StepOnePlus real-time PCR
thermocycler (Applied Biosystems, Carlsbad, CA, USA) using
TaqMan universal PCR master mix and recommended PCR
conditions to assess gene transcript levels quantitatively in the
cell samples. All PCR reactions were performed in triplicate.
Primer sequences are as follows: human S1P receptor 1, 50-
TGC GGG AAG GGA GTA TGT TT-30 (forward) and 50-CCA TCC
CCA CCA CAC TCA AC-30 (reverse); human S1P receptor 2, 50-
GCC TCT CTA CGC CAA GCA TTA-30 (forward) and 50-TTG
AGC GGA CCA CGC AGT A-30 (reverse); human S1P receptor 3,
50-TGA TTG TGG TGA GCG TCT TCA-30 (forward) and 50-GGC
CAC ATC AAT GAG GAA GAG-30 (reverse); human S1P receptor
4, 50-CGG CAC AGC CTC CTC ATT GTC-30 (forward) and 50-
ACA GAC CGA TGC AGC CAT ACA CAC-30 (reverse); for human
S1P receptor 5, 50-CGT CCT GCA TTA CAA CTA CAC C-30
(forward) and 50-GGC CAC ATC AAT GAG GAA GAG-3 0
(reverse); and GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) 50-GCC AAG GTC ATC CAT GAC AAC-30 (forward) and
TABLE. Clinical Characteristics of GO and Non-GO Patients in Our Study
Age Sex Surgery Performed Duration of GO, mo CAS
GO patients 31 F Orbital decompression 16 1
31 M Orbital decompression 156 2
29 F Orbital decompression 50 0
59 M Orbital decompression 144 3
31 F Orbital decompression 18 1
Non-GO control patients 36 F Blepharoplasty n/a n/a
42 F Blepharoplasty n/a n/a
64 F Orbital wall fracture n/a n/a
55 F Orbital wall fracture n/a n/a
45 F Orbital wall fracture n/a n/a
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50-GTC CAC CAC CCT GTT GCT GTA-30 (reverse). All samples
were normalized to the GAPDH values and the results are
expressed as the relative fold change of threshold cycle (Ct)
value relative to the control group using the 2DDCt method.19
Amplification bands were quantified by densitometry and
normalized against corresponding GAPDH bands to control for
PCR variability.
Oil Red O Staining
Cells were stained with Oil Red O as described by Green and
Kehinde.20 A 0.5% (wt/vol) stock solution of Oil Red O in
isopropanol was prepared. For the working solution, 6 mL of the
stock solution was mixed with 4 mL distilled water, left for 1
hour at room temperature, and then filtered through a 0.2-lm
filter. Cells were washed twice with 1x PBS, fixed with 3.7% (wt/
vol) formalin in PBS for 1 hour at 48C, and stained with 300 lL
Oil Red O working solution for 1 hour at room temperature. The
cells were washed with distilled water before being visualized
using an Axio Vert (Carl Zeiss, Jena, Germany) light microscope
and photographed at 340, 3100, and 3200 magnification with
an Olympus BX60 light microscope (Olympus, Melville, NY,
USA). To measure lipid accumulation, cell-bound Oil Red O was
solubilized with 100% isopropanol, and the optical density of the
solution was measured using a spectrophotometer at 490 nm.
Experiments for the quantitative assessment of adipogenic
differentiation were performed in triplicate in cells from
different donors, and the results were normalized to the
absorbance of untreated differentiated control cells.
Western Blot Assays
Differentiated cells were washed with ice-cold PBS and lysed
on ice for 30 minutes in cell lysis buffer consisting of 20 mM
HEPES (pH 7.2), 10% (mol/mol) glycerol, 10 mM Na3VO4, 50
mM NaF, 1 mM phenylmethylsulfonyl fluoride, 0.1 mM
dithiothreitol, 1 lg/mL leupeptin, 1 lg/mL pepstatin, and
1% (mol/mol) Triton X-100. Reagents were obtained from
Sigma-Aldrich Corp. Lysates were centrifuged for 15 minutes
at 21,760g and cell homogenate fractions were stored at
708C before use. Protein concentrations in supernatant
fractions were determined by the Bradford assay (BioRad,
Hercules, CA, USA). Equal amounts of protein (50 lg) were
boiled in sample buffer and resolved by SDS-PAGE in 10% (wt/
mol) gels. The separated proteins were transferred to
polyvinylidene fluoride membranes (Immobilon, Millipore,
Billerica, MA, USA), probed overnight with primary antibod-
ies in Tris Buffer Saline Tween 20, and washed three times
with Tris Buffer Saline Tween 20. Immunoreactive bands
were detected with horseradish peroxidase-conjugated sec-
ondary antibody, and the bound peroxidase was visualized
using an enhanced chemiluminescence kit and exposure to X-
ray film (GE healthcare, Piscataway, NJ, USA). The relative
amount of each immunoreactive band was quantified by
densitometry and normalized to b-actin in the same sample.
Reactive Oxygen Species (ROS) Measurement
Reactive oxygen species release was determined using the
oxidant-sensitive fluorescent probe 5-(and 6)-carboxy-20,70-di-
chloro-dihydrofluorescein diacetate (H2DCFDA; Invitrogen, Eu-
gene, OR, USA) as previously described.21 H2DCFDA is
deacetylated intracellularly by esterase, forming H2DCF, which
is oxidized by ROS to 20,70-dichlorofluorescein (DCF), a highly
fluorescent compound. The cells were seeded at a density of 53
105 cells per well in six-well plates to a total final volume of 2 ml.
The cells were pretreated with 10 lM W146 or 1 lM FTY720 for
1 hour in the presence or absence of 2% cigarette smoke extract
(CSE) or 200 lM H2O2 for 1 hour. The culture medium was then
removed, the cells were washed with PBS, and incubated with 10
lM H2DCFDA at 378C. The cells were then trypsinized, washed,
and resuspended in PBS. Thereafter, fluorescence intensity was
measured using a flow cytometer (ELITE flow cytometer; Coulter
Cytometry, Inc., Hialeah, FL, USA).
Preparation of CSE
Cigarette smoke extract was prepared by bubbling smoke from
two commercially available filtered cigarettes (Marlboro 20
class A cigarettes, containing 8.0 mg of tar and 0.7 mg of
nicotine; Philip Morris Korea, Inc., Seoul, Korea) through 20
mL prewarmed serum-free DMEM/F12 (1:1) at a rate of one
cigarette per 2 minute, as described previously.21 The pH of
the CSE was adjusted to 7.4 and the CSE was filter sterilized
through a 0.2-lM filter (Sartorius Stedim Biotech, Gottingen,
Germany), which was then standardized by measuring its
absorbance (optical density ¼ 0.65 6 0.05 at 320 nm). The
spectrographic pattern of absorbance at 320 nm showed very
little variation between different CSE preparations. The CSE
was freshly prepared within 1 hour of each experiment and
diluted with culture medium, adjusted to a pH of 7.4, and filter
sterilized as described for 10% CSE.
Statistical Analysis
All experiments were performed at least three times and
samples were assayed in duplicate each time. For statistical
analysis of semiquantitative PCR assays and Western blots, the
mean value and SD was calculated for normalized measure-
ments of each mRNA or protein from multiple (‡3) samples
harvested from different individuals. Data between or within
cell groups at different drug concentrations and incubation
times were analyzed by the t-test or ANOVA test and Bonferroni
method as a post hoc test using the SPSS program for
Windows, version 16 (SPSS, Chicago, IL, USA). A P value less
than 0.05 was considered significant.
RESULTS
S1P Receptor 1 Through 5 mRNA Expression in
Orbital Fibroblasts
To compare the expression of S1P receptor mRNAs in GO and
non-GO orbital tissues, we performed relative quantification of
mRNA for each receptor by RT-PCR using whole orbital tissue
explants obtained from five GO and five non-GO control
patients. Sphingosine-1-phosphate 1, S1P2, and S1P3 mRNA
were expressed at relatively high levels in GO orbital tissues
relative to non-GO tissues (*P < 0.05); however, S1P receptor 4
and 5 gene levels were lower in GO tissues (Fig. 1A). We also
measured S1P receptor 1 through 5 mRNA expression on days
0, 4, 7, and 10 of adipocyte differentiation of GO fibroblasts (n
¼ 3) and non-GO fibroblast (n ¼ 3) cultures. All S1P receptor
types were significantly increased during the adipogenesis of
GO fibroblasts. Receptor gene expression seemed to increase
over time and was usually highest on day 7 (Fig. 1B). The
receptor gene expression pattern during adipogenesis of non-
GO fibroblast was similar to that of GO, yet the expression
levels were comparatively low in non-GO cultures.
Effect of S1P on GO Orbital Fibroblast
Adipogenesis
Confluent orbital fibroblasts from GO patients (n ¼ 3) were
subjected to an adipocyte differentiation protocol for 10 days.
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The cells were examined under light microscopy and then
stained with Oil Red O. As previously reported, the orbital
fibroblasts lost their stellate fibroblastic appearance and
converted to a spherical adipocytic shape under the control
adipogenic conditions, and a fraction of these cells accumulated
small lipid droplets.22 To examine whether treating with S1P
had any effect on adipogenesis, different S1P concentrations (0–
1000 ng/mL) were added to the adipogenic medium for 4 days
during the differentiation period, being replaced whenever the
medium was replaced. High-power (3200) microscopic exam-
ination of Oil Red O staining showed that S1P treatment
increased the size and number of adipocytes and increased the
accumulation of lipid droplets with the 250 and 500 ng/mL S1P
treatments showing a prominent increase (Fig. 2A). Western
blot analysis was performed to investigate whether S1P affects
the production of adipogenic transcription factors during
adipogenesis. Each experiment was performed in three GO
cells from different patient samples and was assayed in duplicate
FIGURE 1. Expression of S1P receptor mRNAs in GO and non-GO orbital tissues, and differentiating Graves’ orbital fibroblast cultures. (A)
Comparison of S1P receptor 1 through 5 mRNA expression using real-time PCR between non-GO controls (n¼ 5) and GO (n¼ 5) tissue samples.
Sphingosine-1-phosphate receptor 1, 2, and 3 mRNA expression levels were all significantly higher in GO tissues samples relative to non-GO tissues
(*P < 0.05). (B) Sphingosine-1-phosphate receptor 1 through 5 mRNA expression was significantly increased during the 10 days of adipogenesis in
orbital fibroblast cultures from different non-GO (n¼3, white columns) and GO orbital tissues (n¼3, black columns). The data in the columns are
the mean relative fold of mRNA 6 SD of three experiments (*P < 0.05 versus control undifferentiated cells).
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per each cell sample. As shown in Figure 2B, PPARc and C/EBPa
were enhanced in cells treated with the 250 and 500 ng/mL S1P;
however, C/EBPb did not increase significantly.
Effect of the W146 S1P Receptor 1 Blocker on
Adipogenesis in GO Orbital Fibroblasts
S1P1 receptor inhibitor, a S1P receptor 1 blocker, was added at
different concentrations to the adipogenic medium for the first
4 days during the differentiation period to examine whether
W146 has a suppressive effect on adipogenesis. S1P1 receptor
inhibitor reduced the number of adipocytes and suppressed
the accumulation of lipid droplets, as visualized by microscop-
ic examination after Oil Red O staining (Fig. 3A). The optical
density of stained cell lysates was also measured to evaluate
adipocyte differentiation quantitatively. At 10 and 20 lM
concentrations, W146 treated cells showed significantly
decreased absorbance at 490 nm (P < 0.05). Western blot
analyses were then performed to investigate whether W146
affects the production of the adipogenic transcription factors
PPARc, C/EBPa, and C/EBPb during adipogenesis. PPARc and
C/EBPa proteins were significantly attenuated by 20 lM W146
treatment (Fig. 3B). Each experiment was performed in three
GO cells from different patient samples and was assayed in
duplicate per each cell sample.
Expression of S1P Receptors 1 Through 5 Under
Oxidative Stress Conditions
We measured S1P receptor 1 through 5 mRNA expression
under oxidative stress conditions. Orbital fibroblasts of GO (n
¼ 3) and non-GO (n ¼ 3) patients were exposed to 200 lM
H2O2 or 2% CSE for 0, 1, 3, and 6 hours. All S1P receptor types
were significantly increased under the oxidative stress
conditions induced with H2O2 by 6 hours (Fig. 4A). However,
the expression levels were comparatively low in non-GO
cultures. Two percent of CSE also induced expression of S1P
receptor 1, 2, 3, and 5 mRNA in GO fibroblast cultures by 6
hours, yet the elevation levels in non-GO cultures were not
statistically significant (Fig. 4B).
S1P Receptor Blockers Inhibit HO-1 Production
and ROS Generation in GO Orbital Fibroblasts
Production of the antioxidant enzyme hemeoxygenase-1 (HO-
1) in GO fibroblasts was significantly upregulated by treatment
with 200 lM H2O2 for 4 hours. Pretreatment with S1P receptor
antagonists 10 lM W146 or 1 lM FTY720 for 1 hour
significantly suppressed HO-1 production in cells stimulated
with 200 lM H2O2 (Fig. 4C). In addition, we examined
whether S1P receptor blockers decrease ROS production in
orbital fibroblasts from GO. When pretreated with or without
200 lM H2O2 for 1 hour, treatment of orbital fibroblasts with
the 10 lM W146 or 1 lM FTY720 significantly decreased ROS
levels detected by the ROS-sensitive fluorescent probe, DCFDA
(Fig. 4D). Each experiment was performed in three GO cells
from different patient samples and was assayed in duplicate
per each cell sample.
Signaling Pathway of S1P Action Under H2O2-
Induced Oxidative Stress
To investigate the molecular mechanism of S1P in GO orbital
fibroblasts under oxidative stress conditions, we observed the
effect of S1P on ERK1/2 activation. Sphingosine-1-phosphate at
500 ng/mL provoked a rapid and relevant activation of ERK 1/2
in GO cells, whose phosphorylation was maximal at 30
minutes and declined to basal levels at 180 minutes (Fig. 5A).
FIGURE 2. Effect of S1P on adipogenesis of Graves’ orbital fibroblasts. (A) Different S1P concentrations (100, 250, 500, or 1000 ng/mL) were used to
treat orbital fibroblasts during the first 4 days of adipogenic differentiation. Cells were stained with Oil Red O and examined microscopically (3200).
Adipogenesis was increased by S1P treatment compared with the control. The increased adipocyte differentiation was prominent on Oil Red O
staining when exposed to 250 and 500 ng/mL S1P treatments. The optical density of stained cell lysates also showed significantly increased
absorbance at 490 nm with 250 and 500 ng/mL S1P treatment (*P < 0.05 versus untreated control). (B) Western blot analysis for PPARc, C/EBPa,
and C/EBPb protein production after 10 days of adipogenic differentiation. The experiments were performed in triplicate with cells from three
different donors. Quantification of the PPARc, C/EBPa, and C/EBPb levels by densitometry were normalized to the level of b-actin in the same
sample. The data in the columns are the mean relative density ratios (%) 6 SD of three experiments (*P < 0.05 versus untreated differentiated
control cells).
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Treatment with PD98059 significantly blocked the S1P-
provoked phosphorylation of ERK 1/2 (Fig. 5B). The phos-
phorylation of ERK 1/2 was also strongly enhanced at 30- to 60-
minutes when challenged with 200 lM H2O2 (Fig. 5C). When
cells were pretreated with W146 and FTY720, H2O2-induced
phospho-ERK was significantly inhibited (Fig. 5D). Each
experiment was performed in three GO cells from different
patient samples and was assayed in duplicate per each cell
sample.
Effects of W146 on H2O2- or CSE-Stimulated
Adipogenesis of GO Orbital Fibroblasts
To determine the additive effect of W146 on adipogenesis and
against oxidative stress, we stimulated adipogenesis by addition
of 10 lM H2O2 or 2% CSE along with W146 for the first 3 days of
differentiation. As previously reported by Yoon et al.,23 the
addition of 10 lM H2O2 or 2% CSE significantly increased
adipogenesis compared with that observed under control
conditions, which was assessed with light microscopy (340)
after Oil Red O staining (Fig. 6). When W146 (1–20 lM) was
added to the adipogenic medium for the first 4 days during the
differentiation period, W146 reduced the number of adipocytes
and suppressed the accumulation of lipid droplets induced by
10 lM H2O2 or 2% CSE treatment (Fig. 6). The optical density of
stained cell lysates was also measured to evaluate adipocyte
differentiation quantitatively. The W146-treated cells showed a
decreased absorbance at 490 nm (*P < 0.05, in contrast to cells
treated with 10 lM H2O2 or 2% CSE only).
DISCUSSION
Sphingosine-1-phosphate is involved in many biological activ-
ities including cell proliferation, survival, migration, cytoskel-
etal organization, and morphogenesis.6,24 In this study, we
focused on the role of S1P in GO adipogenesis. Previous
research with 3T3-L1 cells showed that S1P plays a significant
role during adipocyte differentiation.13 FTY720, a functional
antagonist of S1P, was found to downregulate the adipogenesis
of 3T3-L1 preadipocytes.16
In our study, we first identified the distribution of S1P
receptor isoforms in GO tissues in comparison with non-GO
orbital fat tissue, and which showed higher level of S1P
receptor 1, 2, and 3 in GO than in non-GO. Sphingosine-1-
phosphate receptor mRNA expression was significantly in-
creased in GO cells overtime during adipogenic differentiation.
The receptor gene expression patterns of non-GO orbital
fibroblasts during adipogenesis and under oxidative conditions
were similar to that of GO, yet the expression levels were
comparatively low in non-GO cultures. Therefore, we could
assume that the action of S1P and S1P receptor blocker in
adipogenesis and oxidative stress condition would be specific
in GO.
Interestingly, as shown in Figure 1B, all S1P receptor mRNA
expression was increased during the adipogenic differentia-
tion, however S1P receptor 2 to approximately 5 mRNA
decreased from day 7 to day 10. We consider it to be due to the
maturation of preadipocyte to adipocyte at the end of
adipogenic differentiation. Sphingosine-1-phosphate may affect
adipogenesis during the active differentiating phase of
adipogenesis. There is a similar report that activity of
sphingosine kinase, which are responsible for S1P biosynthesis
from sphingosine, was increased in early adipogenic differen-
tiation and decreased after day 6 of adipogenesis and S1P
receptor 1 to approximately 3 mRNA levels were high in
preadipocyte state and declined after full differentiation.25
Exogenous S1P treatment enhanced adipocyte differentiation
as shown in Oil red O stain, and also increased the expression
FIGURE 3. Adipogenesis after S1P receptor blocker treatment. (A) Treatment with the S1P receptor 1 inhibitor W146 for 4 days after induction of
adipogenesis was shown to attenuate adipocyte differentiation as shown with microscopic examination (3100) of Oil Red O staining. The optical
density of stained cell lysates was also measured to evaluate adipocyte differentiation quantitatively. The W146 treated cells at 10 and 20 lM
concentrations showed significantly decreased absorbance at 490 nm (*P < 0.05 versus untreated control). (B) A representative Western blot of
PPARc, C/EBPa, and C/EBPb protein production after 20 lM W146 treatment. PPARc and C/EBPa proteins were significantly attenuated by 20 lM
W146 treatment; however, C/EBPb was not significantly affected. Quantification of PPARc, C/EBPa, and C/EBPb protein levels by densitometry,
normalized to the level of b-actin in the same sample, is shown. The data in the columns are the mean relative density ratios (%) 6 SD of three
experiments (*P < 0.05 versus untreated differentiated control cells).
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of adipogenetic transcriptional markers. Conversely, adipogen-
esis was significantly attenuated by blockade of S1P1 receptor.
In this study, we found that W146 suppressed adipogenesis
in orbital fibroblasts and reduced the protein levels of
adipogenesis-related transcriptional factors, PPARc and C/EBPa.
PPARc and C/EBP transcription factors are produced at distinct
phases during adipogenesis, which have been shown to play
important roles. Sphingosine-1-phosphate 1 receptor antago-
nist, W146 that exhibits no agonist or antagonist activity at
S1P2, S1P3, or S1P5 receptors is known to cause in vivo skin
capillary leakage in murine lung and skin as well as inhibition
of S1P1 agonist-induced lymphocyte sequestration.
26 Our data
suggest that W146 exert antiadipogenic effect by suppressing
these adipogenic transcription factors.
Oxidative stress plays an important role in the pathogenesis
of GO.27,28 Oxygen free radicals contribute to the proliferation
of orbital fibroblasts and glycosaminoglycan production.29
Smoking is the strongest known environmental factor, which
stimulates the development and deterioration of GO by
enhancing ROS generation and adipogenesis.30 H2O2-induced
elevation of superoxide anions can be abolished by antioxidant
treatment, however.31 Recently, selenium (an antioxidant) was
successfully applied in patients with mild GO in a large,
multicenter, randomized, placebo-controlled trial in Europe.32
Antioxidants may exert their actions through antioxidative or
anti-inflammatory effects.
There is a growing evidence that the sphingolipid rheostat
also plays a pivotal role in cellular response to oxidative stress,
determining whether cells survive or proceed to apopto-
sis.33,34 Moderate levels of oxidative stress activate Sphingosine
kinase 1 (SphK1), an enzyme which phophorylates sphingo-
sine to S1P, making a shift in the ceramide-S1P balance toward
S1P, and that suppress apoptosis and maintain cell survival and
proliferation. However, excessive oxidative stress leads to
SphK1 degradation, which decreases S1P, shifting the balance
of the rheostat toward apoptosis. As shown in this study, S1P
FIGURE 4. Effect of oxidative stress on S1P receptors and the S1P receptor blockers on ROS production. (A) After treatment with 200 lM H2O2 for
0, 1, 3, or 6 hours, S1P receptor 1 through 5 gene expression was increased in both non-GO (n¼ 3, white column) and GO (n¼ 3, black column)
orbital fibroblasts (*P < 0.05). A significant increase was detected after a 6-hour H2O2 treatment. (B) After treatment with 2% CSE for 0, 1, 3, and 6
hours, S1P receptor 1 through 5 gene expression showed a significant increase in GO orbital fibroblasts (black column; *P < 0.05 versus control).
However, the increase was not statistically significant in non-GO cultures (white column). (C) Effects of the W146 and FTY720 S1P receptor
blockers on H2O2-stimulated HO-1 production in preadipocyte orbital fibroblasts, analyzed with Western blotting. Orbital fibroblasts (53 105) from
GO patients (n¼3) were pretreated with 10 lM W146 or 1 lM FTY720 for 1 hour, and then stimulated with 200 lM H2O2 for 4 hours to determine
the effect of the S1P receptor antagonists on H2O2-stimulated HO-1 protein production. Quantification of HO-1 by densitometry, normalized to the
level of b-actin in the same sample, is shown. (D) GO orbital fibroblasts were incubated with H2DCFDA 10 lM for 24 hours with 10 lM W146, and 1
lM FTY720 in the presence or absence of 200 lM H2O2 for 1 hour and the fluorescence intensities were analyzed using FACS W146 and FTY720
decreased ROS levels significantly in orbital fibroblasts from GO. Results are expressed as a percentage of untreated control values presented as the
mean 6 SD of three separate experiments (*P < 0.05 versus cells treated with 200 lM H2O2 only).
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seems to play a role in the response to oxidative stress in GO
orbital fibroblasts. In our study, W146 and FTY720 significantly
inhibited H2O2-induced antioxidant enzyme HO-1 production
and ROS generation in GO orbital fibroblasts (Fig. 4). The
induction of HO-1 is considered a part of the protective
response to oxidative stress, as an active defense mechanism.23
Antioxidant enzyme hemeoxygenase-1 was upregulated in
orbital fibroblasts by oxidative stress and pretreatment with
S1P receptor antagonists reduced the production of HO-1. This
reduction in HO-1 seems to be a consequence of the reduction
in intracellular ROS induced by S1P receptor antagonist
activity.
FIGURE 5. Effect of S1P on activation of ERK signal in Graves’ orbital fibroblasts. (A) Treatment with 500 ng/mL S1P provoked activation of ERK 1/
2, phosphorylation of which was maximal at 30 minutes and declined to basal levels at 180 minutes (*P < 0.05 versus untreated control). (B)
Treatment with PD98059 significantly blocked the S1P-provoked phosphorylation of ERK 1/2. (C) The phosphorylation of ERK 1/2 was strongly
enhanced at 30- to 60-minute challenge with 200 lM H2O2. (D) When cells were pretreated with 10 lM W146 and 1 lM FTY720, H2O2-induced
phospho-ERK activation was significantly inhibited. The data in the columns are the mean relative density fold 6 SD of three experiments (*P < 0.05
versus untreated control differentiated cells).
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FIGURE 6. Effects of W146 on H2O2-stimulated adipogenesis. Cells from GO patients (n¼ 3) were treated with 10 lM H2O2 (A) or 2% CSE (B) for
the first 3 days of the 10-day adipogenesis period in adipogenic medium containing 10 lM rosiglitazone. To determine the suppressive effect of
W146 on adipogenesis, W146 (1–20 lM) was also added for the first 4 days of differentiation. The cells were stained with Oil Red O and examined
microscopically (340). The experiments were performed in triplicate with cells from three different GO donors, and representative images are
shown. The optical density of stained cell lysates was also measured (*P < 0.05, in contrast to cells treated with 10 lM H2O2 only).
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We also identified one signaling cascade that appears to
control the action of S1P under oxidative stress. Our results
suggest that H2O2-induced oxidative stress activates the ERK
pathway (Fig. 5). Blockage of the S1P receptor by W146 or
FTY720 strongly attenuated phospho-ERK expression, simi-
lar to blockage by PD98059, implying the involvement of
S1P in the activation of ERK signal by oxidants such as
H2O2. In this study, we used two housekeeping genes,
GAPDH for RT-PCR and b-actin for Western blot assay. In our
laboratory setting, both RNAs were usually constant during
adipogenesis of GO orbital fibroblasts and in oxidative stress
condition.
Oxidative stress in adipose tissue is emerging as an
important mediator of adipocyte dysfunction in obesity,35
which also enhances adipogenesis in GO.23 As we previously
reported, adipogenesis in GO cells was upregulated by the
oxidants H2O2 and CSE, and that this was suppressed by the
S1P1 receptor blocker W146. This suppression of adipogenesis
is overtly due to the composite antiadipogenic and antiox-
idative effects of W146.
Our results imply that the S1P1 receptor might be a
potentially valuable therapeutic target for designing new GO
drugs, especially targeting adipogenesis and oxidative stress.
Given that S1P receptor patterns may be complicated by the
presence of multiple isoforms with opposing actions on the
cell surface, receptor affinity specificity is a key element in
successful S1P receptor-based therapeutic interventions.36 So
far, S1P1 antagonists have not reached clinical development,
yet they are shown to be effective in various disease models
and we are willing to suggest GO as one of new target
diseases.
CONCLUSIONS
Sphingosine-1-phosphate plays a significant role in orbital
adipocyte differentiation in GO and modulation of this
bioactive mediator and its receptor signaling may be a viable
therapeutic target for the treatment of GO.
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